Palvella Therapeutics Inc (PVLA)

$122.06 -14.54 (-10.64%)
Market Cap 1.44B
Revenue (ttm) 0.00
Net Income (ttm) -17.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 521,100
Avg Vol 321,588
Day's Range N/A - N/A
Shares Out 11.84M
Stochastic %K 6%
Beta -0.30
Analysts Strong Sell
Price Target $224.62

Company Profile

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 253 1461
Address:
125 Strafford Avenue, Suite 360, Wayne, United States
Peasant_Speaker
Peasant_Speaker Mar. 4 at 7:29 PM
$PVLA this motherfucker is the brock lesnar of pharma. pleaese give me a damn dip
0 · Reply
Peasant_Speaker
Peasant_Speaker Mar. 3 at 3:29 PM
$PVLA incredible strength
0 · Reply
stockmoe12
stockmoe12 Mar. 3 at 2:21 AM
$QNRX waiting for approval $200M Voucher … should follow same path like $PVLA very soon…
0 · Reply
focafoca99
focafoca99 Mar. 2 at 1:09 PM
$PVLA closes upsized offering with full underwriters’ option exercised — solid demand signal.
0 · Reply
wfinvestor
wfinvestor Feb. 27 at 2:23 AM
$PVLA will this squeeze again tomorrow?
1 · Reply
Smellmahass
Smellmahass Feb. 26 at 10:28 PM
$PVLA Should have held this.
1 · Reply
dadamoni
dadamoni Feb. 26 at 7:37 PM
$PVLA - since my prior prediction (two months ago) , PVLA has gone up by another 30%. I am holding my positions in this baby (300% up in one year).
2 · Reply
Eagley3k
Eagley3k Feb. 26 at 6:28 PM
$PVLA hit my short term target. Out for now.
1 · Reply
KindraJohnson216
KindraJohnson216 Feb. 26 at 3:17 PM
$PVLA
0 · Reply
dthekang
dthekang Feb. 26 at 2:26 PM
$PVLA lfg
0 · Reply
Latest News on PVLA
Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations

Mar 10, 2026, 7:30 AM EDT - 5 days ago

Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations

Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Mar 2, 2026, 7:30 AM EST - 13 days ago

Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Palvella Therapeutics Announces Pricing of Upsized Public Offering

Feb 25, 2026, 7:57 PM EST - 18 days ago

Palvella Therapeutics Announces Pricing of Upsized Public Offering

Palvella Therapeutics Announces Proposed Public Offering

Feb 24, 2026, 4:05 PM EST - 19 days ago

Palvella Therapeutics Announces Proposed Public Offering

Palvella Therapeutics (PVLA) Surges On Positive Phase 3 QTORIN SELVA Data

Feb 24, 2026, 10:15 AM EST - 19 days ago

Palvella Therapeutics (PVLA) Surges On Positive Phase 3 QTORIN SELVA Data

Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations

Feb 24, 2026, 6:30 AM EST - 19 days ago

Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations

Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations

Feb 23, 2026, 5:00 PM EST - 20 days ago

Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations

Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis

Feb 2, 2026, 7:30 AM EST - 5 weeks ago

Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis

These 20 stocks are strong choices for momentum investors

Jan 22, 2026, 10:26 AM EST - 7 weeks ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies

Jan 9, 2026, 7:30 AM EST - 2 months ago

Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies

Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs

Jan 7, 2026, 7:30 AM EST - 2 months ago

Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs

Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst

Dec 23, 2025, 10:43 AM EST - 2 months ago

Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst

Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas

Dec 16, 2025, 7:30 AM EST - 3 months ago

Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas

Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved Therapies

Dec 15, 2025, 6:00 AM EST - 3 months ago

Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved Therapies

Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 11, 2025, 7:30 AM EST - 4 months ago

Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference

Nov 6, 2025, 7:30 AM EST - 4 months ago

Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference

Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies

Nov 5, 2025, 6:00 AM EST - 4 months ago

Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies

Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025

Nov 4, 2025, 7:30 AM EST - 4 months ago

Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025

U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics' Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

Oct 13, 2025, 7:30 AM EDT - 5 months ago

U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics' Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin's Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies

Sep 24, 2025, 6:00 AM EDT - 6 months ago

Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin's Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies

Palvella Therapeutics: QTORIN Nears Phase 3 Readout For MLM

Sep 22, 2025, 7:30 AM EDT - 6 months ago

Palvella Therapeutics: QTORIN Nears Phase 3 Readout For MLM

Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy

Sep 17, 2025, 7:30 AM EDT - 6 months ago

Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy

Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations

Sep 15, 2025, 7:30 AM EDT - 6 months ago

Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D.

Sep 3, 2025, 7:30 AM EDT - 6 months ago

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D.

Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences

Aug 28, 2025, 7:30 AM EDT - 7 months ago

Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences

Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 7:30 AM EDT - 7 months ago

Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025

Aug 7, 2025, 7:30 AM EDT - 7 months ago

Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025

Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 5, 2025, 7:30 AM EDT - 7 months ago

Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

Jun 30, 2025, 7:30 AM EDT - 9 months ago

Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%

Jun 23, 2025, 7:30 AM EDT - 9 months ago

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors

Jun 18, 2025, 7:30 AM EDT - 9 months ago

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors

Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

Jun 9, 2025, 7:30 AM EDT - 9 months ago

Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

May 27, 2025, 8:00 AM EDT - 10 months ago

Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025, 7:30 AM EDT - 10 months ago

Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

May 8, 2025, 7:30 AM EDT - 11 months ago

Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025

May 5, 2025, 7:30 AM EDT - 11 months ago

Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025

Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology

Apr 23, 2025, 4:15 PM EDT - 11 months ago

Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology

Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Apr 22, 2025, 7:30 AM EDT - 11 months ago

Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University's Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology

Apr 11, 2025, 7:30 AM EDT - 1 year ago

Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University's Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology

Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology

Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 31, 2025, 7:30 AM EDT - 1 year ago

Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025

Mar 18, 2025, 8:30 AM EDT - 1 year ago

Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025

Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference

Feb 25, 2025, 8:00 AM EST - 1 year ago

Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old

Feb 10, 2025, 8:00 AM EST - 1 year ago

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old

Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million

Dec 13, 2024, 2:55 PM EST - 1 year ago

Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million

Peasant_Speaker
Peasant_Speaker Mar. 4 at 7:29 PM
$PVLA this motherfucker is the brock lesnar of pharma. pleaese give me a damn dip
0 · Reply
Peasant_Speaker
Peasant_Speaker Mar. 3 at 3:29 PM
$PVLA incredible strength
0 · Reply
stockmoe12
stockmoe12 Mar. 3 at 2:21 AM
$QNRX waiting for approval $200M Voucher … should follow same path like $PVLA very soon…
0 · Reply
focafoca99
focafoca99 Mar. 2 at 1:09 PM
$PVLA closes upsized offering with full underwriters’ option exercised — solid demand signal.
0 · Reply
wfinvestor
wfinvestor Feb. 27 at 2:23 AM
$PVLA will this squeeze again tomorrow?
1 · Reply
Smellmahass
Smellmahass Feb. 26 at 10:28 PM
$PVLA Should have held this.
1 · Reply
dadamoni
dadamoni Feb. 26 at 7:37 PM
$PVLA - since my prior prediction (two months ago) , PVLA has gone up by another 30%. I am holding my positions in this baby (300% up in one year).
2 · Reply
Eagley3k
Eagley3k Feb. 26 at 6:28 PM
$PVLA hit my short term target. Out for now.
1 · Reply
KindraJohnson216
KindraJohnson216 Feb. 26 at 3:17 PM
$PVLA
0 · Reply
dthekang
dthekang Feb. 26 at 2:26 PM
$PVLA lfg
0 · Reply
Trader1141
Trader1141 Feb. 26 at 1:38 PM
$PVLA $RXT $ALBT 🔥🔥🔥
0 · Reply
Trader1141
Trader1141 Feb. 26 at 1:37 PM
$PVLA 😍 52 week high
0 · Reply
Joby099
Joby099 Feb. 26 at 1:27 PM
$UAVS $TLIH $PVLA $CLVT
1 · Reply
Peasant_Speaker
Peasant_Speaker Feb. 26 at 12:57 PM
$PVLA damn insane week just give me some pullback so i can secure a nice entry please
0 · Reply
Djohn2012
Djohn2012 Feb. 26 at 2:32 AM
$PVLA 100% owned by institutions. Low float. MM may run this after the secondary.
1 · Reply
Djohn2012
Djohn2012 Feb. 26 at 2:22 AM
$PVLA Another hidden gem. Only $1.5 Billion market cap. Big Pharma may buy this out before this get noticed. Who will be the suitor? $MRK or $GILD or $PFE. Price targets $210-255
0 · Reply
Djohn2012
Djohn2012 Feb. 26 at 2:08 AM
$PVLA Secondary priced at $125, 1.6 million shares, deal size increased to $200 Million from $150 million. IMHO, high demand for this stock.
1 · Reply
6GodEnergy
6GodEnergy Feb. 25 at 7:46 PM
$BATL $CVRX $PVLA $BNAI ’,’c
0 · Reply
IN0V8
IN0V8 Feb. 25 at 7:08 PM
$PVLA 2/24 Watch / Opportunity H.C. Wainwright raises target price to $255 from $200
0 · Reply
Joby099
Joby099 Feb. 25 at 6:58 PM
$UAVS $TLIH $PVLA $CLVT
1 · Reply
Joby099
Joby099 Feb. 25 at 11:25 AM
$UAVS $TLIH $PVLA $CLVT
0 · Reply
erevnon
erevnon Feb. 25 at 11:19 AM
BTIG maintains Palvella Therapeutics $PVLA at Buy and raises the price target from $192 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply